Magnesium Supplementation Modulates T-cell Function in People with Type 2 Diabetes and Low Serum Magnesium Levels
Drenthen LCA, Ajie M, de Baaij JHF, Tack CJ, de Galan BE, Stienstra R
The Journal of clinical endocrinology and metabolism · 7 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
- Nonprofit
- Diabetes Fonds
- Nonprofit
- Dutch Diabetes Research Foundation
- Grants
- Diabetes Fonds (2017.81.014)
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2024-02-27 · J Clin Endocrinol Metab · vol. 109 · issue 12 · pp. e2240–e2245
- Publisher
- Oxford University Press
- Cited
- 9 citations · more than 83% of similar papers · 1.9× the field average
- References
- 22 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- Magnesium, Type 2 diabetes, Endocrinology, Internal medicine, Function (biology), Diabetes mellitus, Cell function, Medicine, Chemistry, Cell, Biology, Biochemistry, Cell biology
- MeSH
- t-lymphocytes, cd8-positive t-lymphocytes, humans, diabetes mellitus, type 2, magnesium deficiency, magnesium, cross-over studies, double-blind method, dietary supplements, aged, middle aged, female, male
6 authors
From NL
- Linda C. A. Drenthen · correspondingRadboud University Nijmegen; Radboud University Medical Center; Radboud Institute for Molecular Life Sciences
- Mandala AjieRadboud University Nijmegen; Radboud University Medical Center; Radboud Institute for Molecular Life Sciences
- Jeroen H. F. de BaaijRadboud University Nijmegen; Radboud University Medical Center
- Cees J. TackRadboud University Nijmegen; Radboud University Medical Center; Radboud Institute for Molecular Life Sciences
- Bastiaan E. de GalanRadboud University Nijmegen; Maastricht University Medical Centre; Radboud University Medical Center; Maastricht University; Radboud Institute for Molecular Life Sciences
- Rinke StienstraRadboud University Nijmegen; Radboud University Medical Center; Radboud Institute for Molecular Life Sciences; Wageningen University & Research
Abstract
Context
Low magnesium levels, which are common in people with type 2 diabetes, are associated with increased levels of proinflammatory molecules. It is unknown whether magnesium supplementation decreases this low-grade inflammation in people with type 2 diabetes.
Objective
We performed multidimensional immunophenotyping to better understand the effect of magnesium supplementation on the immune system of people with type 2 diabetes and low magnesium levels.
Methods
Using a randomized, double-blind, placebo-controlled, 2-period, crossover study, we compared the effect of magnesium supplementation (15 mmol/day) with placebo on the immunophenotype, including whole blood immune cell counts, T-cell and CD14+ monocyte function after ex vivo stimulation, and the circulating inflammatory proteome.
Results
We included 12 adults with insulin-treated type 2 diabetes (7 males, mean ± SD age 67 ± 7 years, body mass index 31 ± 5 kg/m2, HbA1c 7.5 ± 0.9%) and low magnesium levels (0.73 ± 0.05 mmol/L). Magnesium treatment significantly increased serum magnesium and urinary magnesium excretion compared with placebo. Interferon-γ production from phorbol myristate acetate/ionomycin stimulated CD8+ T-cells and T-helper 1 cells, as well as interleukin (IL) 4/IL5/IL13 production from T-helper 2 cells was lower after treatment with magnesium compared with placebo. Magnesium supplementation did not affect immune cell numbers, ex vivo monocyte function, and circulating inflammatory proteins, although we found a tendency for lower high sensitivity C-reactive protein levels after magnesium supplementation compared with placebo.
Conclusion
In conclusion, magnesium supplementation modulates the function of CD4+ and CD8+ T-cells in people with type 2 diabetes and low serum magnesium levels.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.